Gardiquimod, an imidazoquinoline compound, is a novel, potent and specific agonist of TLR7 (toll-like receptor 7) with antitumor and immunomodulatory effects. It also inhibits HIV-1 reverse transcriptase. Gardiquimod can promote the proliferation of murine splenocytes, stimulate the activation of splenic T, NK and natural killer T (NKT) cells, increase the cytolytic activity of splenocytes against B16 and MCA-38 tumor cell lines, and enhance the expression of costimulatory molecules and IL-12 by macrophages and bone marrow-derived dendritic cells (DCs). In a murine model, Gardiquimod improved the antitumor effects of tumor lysate-loaded DCs, resulting in delayed growth of subcutaneous B16 melanoma tumors and suppression of pulmonary metastasis. Gardiquimod demonstrated more potent antitumor activity than imiquimod. These results suggest that TLR7/8 agonists such as Gardiquimod may serve as potent innate and adaptive immune response modifiers in tumor therapy. More importantly, they can be used as vaccine adjuvants to potentiate the efficiency of DC-based tumor immunotherapy.

纯度：≥98%

CAS：1020412-43-4